Amgen Awarded Breakthrough Designation for Acquired Cancer Antibody Drug

One month after snapping up Five Prime Therapeutics and its Phase III ready anti-FGFR2b antibody bemarituzumab for $1.9 billion, Amgen announced the U.S. Food and Drug Administration (FDA) awarded Breakthrough Therapy Designation to the asset as a first-line treatment for certain types of gastric cancer. Late Monday, Amgen announced the investigational drug bemarituzumab received the FDA’s designation for patients with fibroblast growth factor receptor 2b (FGFR2b).
Read more...

;